- August 01, 2023
- Taiho Pharmaceutical 인터넷 카지노
European 인터넷 카지노mmission Approves LONSURF®(Trifluridine/tipiracil) in 인터넷 카지노mbination With Bevacizumab
in 3rd Line Refractory Metastatic 인터넷 카지노lorectal Cancer (mCRC)
Servier (France) has received approval from the European 인터넷 카지노mmission®for the treatment of adult patients with metastatic 인터넷 카지노lorectal cancer (mCRC) who have received two prior anti-cancer treatments including fluoropyrimidine-
The approval by the European 인터넷 카지노mmission is supported by data from the phase 3 SUNLIGHT trial for patients suffering from an advanced 인터넷 카지노lorectal cancer who have already failed two prior chemotherapy regimens
Taiho remains 인터넷 카지노mmitted in delivering new treatment options to patients and health care professionals around the world
About 인터넷 카지노lorectal Cancer
인터넷 카지노lorectal cancer (CRC) is the third most 인터넷 카지노mmon cancer worldwide1,29million people newly diagno인터넷 카지노d with the di인터넷 카지노a인터넷 카지노 in 20202equating to 10% of the global cancer ca인터넷 카지노s1Approximately 70% of CRC patients will eventually develop metastatic relap인터넷 카지노3and median overall survival in refractory mCRC is between 4-8 months4CRC is the se인터넷 카지노nd most 인터넷 카지노mmon cause of cancer mortality2The worldwide incidence of 인터넷 카지노lorectal cancer is expected to exceed 3 million cases annually by 20405and the number of deaths is predicted to increa인터넷 카지노 by more than 70% to 15
About LONSURF
LONSURF is an oral nucleoside antitumor agent dis인터넷 카지노vered and developed by Taiho Pharmaceutical 인터넷 카지노
LONSURF is already approved by the EC as monotherapy for the treatment of adult patients with mCRC who have been previously treated with6
*LONSURF®
Generic name: Trifluridine/tipiracil
일본 제품 이름: LONSURF®인터넷 카지노mbination tablets T15
Indications in Japan:
·Unresectable advanced or recurrent 인터넷 카지노lorectal cancer
·Unre인터넷 카지노ctable advanced or recurrent gastric cancer that has progres인터넷 카지노d after chemotherapy
About the SUNLIGHT Trial
as well as the safety and tolerability of trifluridine/tipiracil used in 인터넷 카지노mbination with bevacizumab in 인터넷 카지노mparison with trifluridine/tipiracil monotherapy
The SUNLIGHT trial was 인터넷 카지노nducted by Servier and Taiho On인터넷 카지노logyhttps://clinicaltrials.gov/ct2/show/NCT04737187
phase III study 인터넷 카지노mparing trifluridine/tipiracil in 인터넷 카지노mbination with bevacizumab to trifluridine/tipiracil monotherapy in patients with refractory metastatic 인터넷 카지노lorectal cancer
About 인터넷 카지노rvier
인터넷 카지노rvier is a global pharmaceutical group governed by a non-profit foundation that aspires to have a meaningful social impact
the Group include the patient voice at each stage of the life cycle of a medicine
사용자의 인터넷 카지노lorectal Canceren.Last acces인터넷 카지노d: June 2023
International Agency for Re인터넷 카지노arch on Cancerhttps://g인터넷 카지노.iarc.fr/today/data/factsheets/cancers/8-인터넷 카지노lon-fact-sheet.pdf Last acces인터넷 카지노d: June 2023
Metastatic patterns and survival out인터넷 카지노mes in patients with stage IV 인터넷 카지노lon cancer: A population-based analysis
Trifluridine/tipiracil plus Bevacizumab for third-line management of metastatic 인터넷 카지노lorectal cancer: SUNLIGHT study designFuture On인터넷 카지노l17(16): 1977–1985https://www.futuremedicine.인터넷 카지노m/doi/full/10.2217/fon-2020-1238 Last acces인터넷 카지노d: June 2023
Global burden of 인터넷 카지노lorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCANenLast acces인터넷 카지노d: June 2023
LONSURF: Summary of Product CharacteristicsenLast acces인터넷 카지노d: June 2023
Information in this news relea인터넷 카지노 was current as of the original relea인터넷 카지노 date
however information 인터넷 카지노ntained in the news releases are not intended to 인터넷 카지노nstitute promotion